Loading…
Employees: 763
Size Xizang Weixinkang Pharmaceutical (603676.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $538M, the 3684th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥8.24 on 6 Nov 2026.
Performance Over six months the shares fell 22.3%, against -13.9% for the median peer and -16.4% for the China market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue fell 8.3% over the last twelve months (peer median +7.9%); the operating margin is 16.1% (peer median 6.5%).
Valuation It trades at 2.4× enterprise value to sales against a peer median of 5.4× (6th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -15 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 22.7 points above its cost of capital (5.0% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.07B | CN¥1.12B | CN¥1.29B | CN¥1.31B | CN¥1.39B |
| Revenue growth | — | -13% | -2% | -5% | — |
| Gross profit | CN¥640M | CN¥654M | CN¥658M | CN¥618M | CN¥686M |
| EBITDA | n/a | CN¥269M | CN¥281M | CN¥194M | CN¥208M |
| Net income | CN¥190M | CN¥233M | CN¥246M | CN¥214M | CN¥177M |
| Free cash flow | CN¥157M | CN¥123M | CN¥339M | CN¥186M | CN¥184M |
| Capital expenditure | CN¥90.2M | CN¥83.9M | CN¥58.2M | CN¥70.8M | CN¥77.7M |
| Total debt | CN¥9.45M | CN¥11.2M | CN¥5.27M | CN¥30.1M | CN¥29.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603676.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.9% | -10.0% | 10th highest of 21 |
| 6-month return | -22.3% | -13.9% | 7th lowest of 21 |
| Distance from 52-week high | -31.5% | -32.1% | 10th highest of 21 |
| Revenue growth (TTM) | -8.3% | +7.9% | 5th lowest of 21 |
| Operating margin | 16.1% | 6.5% | 5th highest of 19 |
| EV / Sales | 2.4× | 5.4× | 6th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | -5.2% | 6.7% | 3rd least demanding of 8 |
| Growth delivered (Del g) | +9.6% | +9.1% | 4th highest of 8 |
| Hurdle (Req g minus delivered) | -14.8 pp | -11.5 pp | 4th least demanding of 8 |
| ROIC minus cost of capital | +22.7 pp | -3.5 pp | 3rd highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $538M | -22% | -8% | 16% | 2.4× | -5.2% | +9.6% |
| Zeria Pharmaceutical 4559.T | Japan | $540M | -6% | +12% | 15% | 1.0× | -12.5% | +11.1% |
| ChengDa PharmaCeuticals 301201.SZ | China | $535M | -43% | +27% | -9% | 5.7× | n/a | n/a |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $533M | -5% | -5% | 7% | 2.7× | 17.7% | +4.4% |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $544M | -14% | +10% | 39% | 5.3× | -3.9% | +7.6% |
| Boryung 003850.KS | South Korea | $531M | -14% | +6% | 6% | 0.7× | -8.9% | +12.6% |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $546M | -44% | +14% | 0% | 1.9× | n/a | n/a |
| Entera Bio ENTX | United States | $546M | +142% | -100% | n/a | n/a | n/a | n/a |
| Morepen Laboratories MOREPENLAB.NS | India | $529M | +110% | +30% | 11% | 2.2× | n/a | n/a |
| Egetis Therapeutics EGTX.ST | Sweden | $528M | +67% | +39% | -604% | 73.5× | n/a | n/a |
| Orchid Pharma ORCHPHARMA.NS | India | $551M | +27% | +11% | 0% | 5.5× | n/a | n/a |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $525M | +43% | +68% | 37% | 11.3× | 12.9% | +126.7% |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $524M | -5% | +18% | 39% | 28.5× | n/a | n/a |
| Newland Pharmaceutical 301277.SZ | China | $523M | -22% | +9% | 11% | 3.9× | 10.2% | +9.1% |
| Capricor Therapeutics CAPR | United States | $523M | -73% | -100% | n/a | n/a | n/a | n/a |
| Chimin Health Management 603222.SS | China | $553M | -28% | +1% | -28% | 6.8× | n/a | n/a |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $520M | -20% | -1% | 10% | 2.1× | n/a | n/a |
| Ovid Therapeutics OVID | United States | $557M | +2% | -76% | -3,687% | 285.6× | n/a | n/a |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $519M | -18% | -4% | 18% | 4.0× | 6.7% | -4.1% |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $514M | -32% | -4% | -11% | 9.8× | n/a | n/a |
| Beijing Science Sun Pharmaceutical 300485.SZ | China | $566M | -28% | -11% | -8% | 6.5× | n/a | n/a |